West Pharmaceutical Services (WST) came out with quarterly earnings of $1.85 per share, beating the Zacks Consensus Estimate of $1.51 per share. This compares to earnings of $2.16 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 22.52%. A quarter ago, it was expected that this medical device company would post earnings of $1.77 per share when it actually produced earnings of $1.52, delivering a surprise of -14.12%.Over the last ...

Exhibit 99.1 https://files.reportify.cc/media/production/WST4135fcd308fa West Announces Third-Quarter 2024 Results, Increases Fiscal Year 2024 Guidance and Declares FourthQuarter 2024 Dividend - Conference Call Scheduled for 9 a.m. EDT Today - Exton, PA, October 24, 2024 – West Pharmaceutical Services, Inc. (NYSE: WST) today announced its financial results for the third-quarter 2024 and declared a fourth-quarter 2024 dividend. Third-Quarter 2024 Summary (comparisons to prior-year period) • Net sales of $746 ...

- Conference Call Scheduled for 9 a.m. EDT Today -EXTON, Pa., Oct. 24, 2024 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST) today announced its financial results for the third-quarter 2024 and declared a fourth-quarter 2024 dividend.Third-Quarter 2024 Summary (comparisons to prior-year period)Net sales of $746.9 million declined 0.1%; organic net sales decline was 0.5%.Reported-diluted EPS of $1.85, compared to $2.14 in the same period last year.Adjusted-diluted EPS of $1.85, compared to $2.1 ...

EXTON, Pa., Oct. 22, 2024 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced participation in the 2024 PDA Universe of Pre-Filled Syringes and Injection Devices Conference in Phoenix, AZ to showcase its leadership and expertise on industry challenges and trends in packaging and containment. "With the rise of biologic drugs, injectables are the fastest growing drug segment today, bringing with it new chal ...

West Pharmaceutical Services (WST) is scheduled to release third-quarter 2024 results on Oct. 10, before the opening bell. In the last reported quarter, the company delivered an earnings miss of 14.12%. WST’s earnings beat estimates in three of the trailing four quarters and missed once, delivering an average surprise of 6.44%.Stay up-to-date with all quarterly releases: See Zacks Earnings Calendar.Q3 EstimatesCurrently, the Zacks Consensus Estimate for revenues is pegged at $710.2 million, indicating a dec ...

EXTON, Pa., Oct. 10, 2024 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that it will release third-quarter financial results before the market opens on Thursday, October 24, 2024, and will follow with a conference call to discuss the results and business expectations at 9:00 a.m. Eastern Time. The live webcast will be made available via the Company's Investor Relations website click here. To ask que ...

EXTON, Pa., Sept. 5, 2024 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that it will present at the Bank of America Global Healthcare Conference in London, UK on Wednesday, September 18, 2024, at 9:55 AM BST. A live audio webcast of the event will be available in the "Investors" section of the Company's website at www.westpharma.com. Replay of the webcasts will be available for approximately 90 days ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to WEST PHARMACEUTICAL SERVICES, INC. (Exact name of registrant as specified in its charter) Pennsylvania 23-1210010 (State or other jurisdiction of incorporation or org ...

West Pharmaceutical Services, Inc. (NYSE:WST) Q2 2024 Earnings Conference Call July 25, 2024 9:00 AM ET Company Participants John Sweeney - Head of IR Eric Green - CEO Bernard Birkett - SVP, Chief Financial and Operations Officer Conference Call Participants Paul Knight - KeyBanc Capital Markets Larry Solow - CJS Securities Justin Bowers - Deutsche Bank Mike Ryskin - Bank of America Matt Larew - William Blair & Company Jacob Johnson - Stephens Dan Leonard - UBS David Windley - Jefferies Tom DeBourcy - Nephr ...

The adjustments include expenses related to the amortization of acquisition-related intangible assets. Revenues in Detail The company recorded an organic net sales decline of 5.9% in the reported quarter. Segmental Details Net sales in the Proprietary Products segment were $559.7 million, indicating a decline of 9.4% year over year and 8.4% on an organic basis. HVP net sales, which accounted for more than 70% of the segment's net sales, were driven by customer demand for self-injection, Envision® components ...